FinancialContent is the trusted provider of stock market information to the media industry.
July 31, 2013 at 11:30 AM EDT
RDInvesting Provides Investors with Free In-Depth Equity Reports on AEG, AVD, UTHR and XYL

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

AEGON N.V. (NYSE: AEG) shares declined 1.56 percent to close at $7.56 a share Tuesday. The stock traded between $7.52 and $7.76 on volume of 1.75 million shares traded. Analysts at Goldman have recently downgraded the company’s rating to "neutral" from "buy". Shares of AEGON have fallen approximately 17.4 percent year-to-date.

Find out more about AEGON including full access to the free equity report at:

www.RDInvesting.com/AEG

American Vanguard Corp. (NYSE: AVD) shares declined 2.14 percent to close at $24.70 a share Tuesday. The stock traded between $24.65 and $25.23 on volume of 742,028 shares traded. Analysts at SunTrust have recently initiated coverage on the company with a "neutral" rating. Shares of American Vanguard have fallen approximately 20.0 percent year-to-date.

Find out more about American Vanguard including full access to the free equity report at:

www.RDInvesting.com/AVD

United Therapeutics Corporation (NASDAQ: UTHR) shares gained 1.54 percent to close at $73.75 a share Tuesday. The stock traded between $72.70 and $74.64 on volume of 964,222 shares traded. Analysts at Standpoint Research have recently downgraded the company’s rating to "hold" from "buy". Shares of United Therapeutics have fallen approximately 17.4 percent year-to-date.

Find out more about United Therapeutics including full access to the free equity report at:

www.RDInvesting.com/UTHR

Xylem Inc. (NYSE: XYL) shares dropped 10.26 percent to close at $25.54 a share Tuesday. The stock traded between $23.61 and $26.68 on volume of 10.02 million shares traded. Analysts at BB&T have recently downgraded the company’s rating to "hold" from "buy". Shares of Xylem have fallen approximately 5.7 percent year-to-date.

Find out more about Xylem including full access to the free equity report at:

www.RDInvesting.com/XYL

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:

Research Driven Investing

info@rdinvesting.com

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here
   
Financial Widgets

Display market data, financial news or stock quotes - Learn More

Advertising Network

Advertise on FinancialContent's huge network - Learn More

Web Services

Power your internet and wireless applications - Learn More